CareRx Corporation Receives Regulatory Approval for Launch of its Normal Course Issuer Bid
TORONTO, Sept. 5, 2023 /CNW/ - CareRx Corporation ("CareRx" or "the Company") (TSX: CRRX) today announced that the Toronto Stock Exchange (the "TSX") has approved the Company's previously announced normal course issuer bid (the "NCIB") to purchase for cancellation up to 1,000,000 of its common shares ("Shares"), representing approximately 1.73% of its 57,743,726 issued and outstanding Shares as at August 31, 2023.
It is expected that the NCIB will begin on September 7, 2023 and will end on September 6, 2024. Daily purchases on the TSX under the NCIB will be limited to 4,624 Shares, other than purchases made pursuant to the block purchase exception, being 25% of the average daily trading volume on the TSX for the six months ending July 31, 2023. The actual number of Shares to be purchased, and the timing of any such purchases, will be determined by the Company, subject to the applicable rules and policies of the TSX. All Shares acquired will be cancelled.
Although the Company presently intends to purchase Shares under its NCIB, there can be no assurances that any such purchases will be completed. The purchases will be made through the facilities of the TSX and/or any alternative trading system in Canada. The Company will pay the market price for the common shares at the time of acquisition and the purchases will be made in accordance with applicable regulatory requirements.
CareRx is Canada's leading provider of pharmacy services to seniors living communities. We serve over 95,000 residents in over 1,500 seniors and other congregate care communities (long-term care homes, retirement homes, assisted living facilities, and group homes). We are a national organization with a large network of pharmacy fulfillment centres strategically located across the country. This allows us to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. We use best-in-class technology that automates the preparation and verification of multi-dose compliance packaging of medication, providing the highest levels of safety and adherence for individuals with complex medication regimes. We take an active role in working with our home operator partners to promote resident health, staff education, and medication system quality and efficiency.
This press release contains statements that may constitute "forward-looking statements" within the meaning of applicable Canadian securities legislation, including statements relating to the NCIB. These forward-looking statements include, among others, statements regarding the Company's business strategy, plans and other expectations, beliefs, goals, objectives, information and statements about possible future events. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate" or similar expressions suggesting future outcomes or events. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management.
Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by such statements. Factors that could cause such differences include the Company's general business risks, exposure to and reliance on government regulation and funding, the Company's liquidity and capital requirements, exposure to epidemic or pandemic outbreak, reliance on contracts with key customers and other risk factors described from time to time in the reports and disclosure documents filed by the Company with Canadian securities regulatory agencies and commissions. These and other factors should be considered carefully and readers should not place undue reliance on the Company's forward-looking statements. As a result of the foregoing and other factors, no assurance can be given as to any such future results, levels of activity or achievements and neither the Company nor any other person assumes responsibility for the accuracy and completeness of these forward-looking statements. The factors underlying current expectations are dynamic and subject to change.
SOURCE CareRX Corporation
Upcoming Life Sciences Events
- December 2023
- Marseille: BioFIT
- January 2024
- San Francisco: 7th Annual Neuroscience Innovation Forum
- Biotech Showcase™
Latest company news
New Israeli cannabis regulation, facilitating access for many new patients, scheduled for December 29, 2023, has been postponed by three months; Israeli Ministry of Health published a new report showing a surge in new medical cannabis patients in Nov